HOB Biotech Group (HOB) (hereinafter referred to as "HOB") was successfully listed on Shanghai Stock Exchange on Jan. 13th, 2021 with the stock code of 688656. The issue price was ￥35.26 yuan per share, up to ￥75.88 yuan in the first half of an hour.
HOB Biotech Group (HOB) is an innovative in vitro diagnostic company founded by overseas returnees with education and decades of industrial experience in the United States. It` s specialized in providing diagnostic tools to laboratories and hospitals for the improvement of allergy and autoimmune disease patient care. The company is highly committed to providing innovative and effective, "affordable and reliable" diagnostic products for patients worldwide.
Since established in 2009, with dedicated R&D investment, HOB has gradually become in China the market leader in allergy diagnostics and a rising star in autoimmune diagnostics. It has established a world-class global R&D center in Suzhou, China and California, US, with a well experienced IVD product development team. HOB established a large-scale, ISO 13485 certified manufacturing facility in Suzhou, China, providing high quality products ranging from line immuno assay (BioLINE), enzyme-linked immunosorbent assay (BioLISA) to more advanced chemiluminescent paramagnetic microparticle immuno assay (BioCLIA). The company strives to meet customer needs and continuously improve our service capabilities. And has built a customer service team covering 34 provinces and municipalities across China to provide professional technical service in a timely manner.
HOB’s mission is to develop and offer customers “affordable and reliable” products in allergy and autoimmune in vitro diagnostics, with the-state-of-art technologies, top-notch quality, and competitive pricing. As a leading manufacturer with strong R&D capability, HOB is expanding its global influence by forming strategic alliances with companies worldwide to provide high-quality and cost-effective products.
Shanghai Liferiver Biotech Co., Ltd. (hereinafter referred to as "Liferiver") was successfully listed on Shanghai Stock Exchange on Jan. 18th, 2021 with the stock code of 688317. The issue price was ￥43.22 yuan per share, up to ￥92.88 yuan in the first half of an hour.
Established in 2005, as a high-tech enterprise specializing in the R & D, production and sales of genetic diagnostic reagents and equipment, Liferiver is one of the leading enterprises in the production of molecular diagnostic reagents in China. It is a leading PCR-based molecular diagnostics solution provider, developing, manufacturing & marketing real time PCR diagnostic kits as well as instruments. The company offers over 400 testing kits covering most infectious diseases, genetic diseases, tumors, organ transplants & others. Its kits are compatible with most real time PCR systems of various brands including ABI, Bio-Rad and Roche. Their products are available in more than 70 countries. With offices in both China & US, the company is compliant with ISO13485. Most of the products are CE marked. Liferiver Bio-Tech (United States) Corp. is in San Diego of California, one of America’s three major life science bases. With an office building of nearly 6,000 ft2, it focuses on emerging technologies & product research as well as development of global markets especially US market.
During the outbreak of COVID-19, the company responded quickly with the accumulated experience and technology. Firstly, it took the initiative to lead the team in tackling key problems in scientific research and played an important role in promoting scientific prevention and control and scientific treatment. On Jan. 26th, 2020, Liferiver became the first batch of enterprise whom obtained the certificate of novel coronavirus detection kit authorized by NMPA in China, also, obtained the CE mark on Feb. 26th, then got the TGA from Australia, SAHPRA from South Africa, PFDA from Philippine, CDSCO from India, MDA from Malaysia, HSA from Singapore, etc. On May, 22nd, the certificate of COVID-19 detecting kit passed by WHO and listed on EUL.
